Related references
Note: Only part of the references are listed.Core Needle Lung Biopsy Specimens: Adequacy for EGFR and KRAS Mutational Analysis
Stephen B. Solomon et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2010)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment
D. Ross Camidge et al.
CLINICAL CANCER RESEARCH (2010)
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations
I. Garcia-Olive et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma <= 1 cm Is Not Justified
Amod A. Sarnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer: A Panacea or Just an Obstacle Course for the Patient?
Vijay P. Khatri
JOURNAL OF CLINICAL ONCOLOGY (2010)
Second-Line Therapy for Elderly Patients with Non-small Cell Lung Cancer Who Failed Previous Chemotherapy Is as Effective as for Younger Patients
Chieh-Hung Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology A Paradigm Shift
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop
Robert Pirker et al.
Journal of Thoracic Oncology (2010)
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
Federico Cappuzzo et al.
LANCET ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2010)
EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases
Katharina Schmid et al.
CLINICAL CANCER RESEARCH (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
Long-term survival expectations of cancer patients in Europe in 2000-2002
Hermann Brenner et al.
EUROPEAN JOURNAL OF CANCER (2009)
Pulmonary adenocarcinomas: classification and reporting
Keith M. Kerr
HISTOPATHOLOGY (2009)
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors
Tobias Walbert et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2009)
Meta-Analysis of Single-Agent Chemotherapy Compared With Combination Chemotherapy As Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Massimo Di Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non-Small-Cell Lung Cancer
Panos M. Fidias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials
Rogerio Lilenbaum et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu et al.
LANCET (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
Cesare Gridelli et al.
ONCOLOGIST (2009)
Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
Rafael Rosell et al.
PLOS ONE (2009)
Lung adenocarcinoma:: Modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis
Noriko Motoi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
PIK3CA mutations and copy number gains in human lung cancers
Hiromasa Yamamoto et al.
CANCER RESEARCH (2008)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
S. Burdett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer
Corey J. Langer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Detection of mutations in EGFR in circulating lung-cancer cells
Shyamala Maheswaran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
Ioannis Boukovinas et al.
PLOS ONE (2008)
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression:: A phase III trial in non-small-cell lung cancer
Manuel Cobo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history
Mounia Mounawar et al.
CANCER RESEARCH (2007)
Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Andrea Ardizzoni et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine
P. Ceppi et al.
ANNALS OF ONCOLOGY (2006)
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
C. von Plessen et al.
BRITISH JOURNAL OF CANCER (2006)
Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
Glen J. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Monitoring standards for molecular genetic testing in the United Kingdom, The Netherlands, and Ireland
Simon C. Ramsden et al.
GENETIC TESTING (2006)
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer
Michio Inukai et al.
CANCER RESEARCH (2006)
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based?: A meta-analysis of phase III randomized trials
JL Pujol et al.
LUNG CANCER (2006)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature
G D'Addario et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas
H Shigematsu et al.
CANCER RESEARCH (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
C Gridelli et al.
ANNALS OF ONCOLOGY (2004)
Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer
K Hotta et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer
K Hotta et al.
LUNG CANCER (2004)
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
M Taron et al.
HUMAN MOLECULAR GENETICS (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group
F Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer
R Rosell et al.
ONCOGENE (2003)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer
E Massarelli et al.
LUNG CANCER (2003)
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer
GV Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
CA Dykewicz
CLINICAL INFECTIOUS DISEASES (2001)
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1
G Robinet et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
